Private equity investment firm Amulet – which was founded last year – paid former SynterActHCR owner Gryphon Investors an undisclosed sum for the Phase I-IV focused clinical services firm.
SynteractHCR CEO Wendel Barr said funding from the CROs new owners will “allow us to enhance our full service capabilities, hire even more international clinical development experts to support global trials.”
Gryphon bought Synteract in 2008. In 2013, Gryphon bought Munich-based Harrison Clinical Research and merged it Synteract citing a desire to expand the firm’s presence in Europe and to move into the medical device contracting space as a major motivation.